Imiquimod in basal cell carcinoma: How does it work?

British Journal of Dermatology, Supplement

Volumn 149, Issue 66, 2003, Pages 57-58

  Dummer, R ^a   Urosevic, M ^a   Kempf, W ^a   Hoek, K ^a   Hafner, J ^a   Burg, G ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Apoptosis; Basal cell carcinoma; Imiquimod; Immunotherapy

Indexed keywords

ALPHA INTERFERON; IMIQUIMOD; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; UNCLASSIFIED DRUG;

APOPTOSIS; BASAL CELL CARCINOMA; CANCER REGRESSION; CONFERENCE PAPER; CREAM; DNA MICROARRAY; DRUG DOSE REGIMEN; GENETIC ANALYSIS; HISTOLOGY; HUMAN; IMMUNE RESPONSE; IMMUNOCHEMISTRY; MACROPHAGE; MONOCYTE; PRIORITY JOURNAL; TUMOR BIOPSY;

EID: 0346690036     PISSN: 0366077X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0366-077x.2003.05630.x     Document Type: Conference Paper

References (8)

1. Urosevic M, Dummer R. Immunotherapy for nonmelanoma skin cancer: does it have a future? Cancer 2002; 94: 477-85.
2. Ries LAG, Wingo PA, Miller DS et al. The annual report to the nation on the status of cancer. 1973-97. with a special section on colorectal cancer. Cancer 2000; 88: 2398-424.
3. Mardi I, Stern RS. Risk of developing a subsequent nonmelanoma skin cancer in patients with a history of nonmelanoma skin cancer: a critical review of the literature and meta-analysis. Arch Dermatol 2000; 136: 1524-30.
4. Nestle FO, Burg G, Fah J, Wrone Smith T, Nickoloff BJ. Human sunlight-induced basal-cell-carcinoma-associated dendritic cells are deficient in T cell co-stimulatory molecules and are impaired as antigen-presenting cells. Am J Pathol 1997; 150: 641-51.
5. Urosevic M, Maier T, Benninghoff B et al. Mechanisms underlying imiquimod-induced regression of basal cell carcinoma in vivo. Arch Dermatol 2003; in press.
6. Hemmi H, Kaisho T, Takeuchi O et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 2002; 3: 196-200.
7. Jurk M, Heil F, Vollmer J et al. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat Immunol 2002; 3: 499.
8. Armant MA, Fenton MJ. Toll-like receptors, a family of pattern-recognition receptors in mammals. Genome Biol 2002; 3: S3011.1-S3011.6.